81 related articles for article (PubMed ID: 2734533)
1. [Validity of Gynaegnost in the follow-up of patients treated for ovarian cancer].
Cerejeira L; Pinto-Ferreira MM; Otilia-Bacelar MO; Moutinho J
Rev Fr Gynecol Obstet; 1989 Apr; 84(4):347-9. PubMed ID: 2734533
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic value of increased lactate dehydrogenase activity in vaginal secretions for the early detection of diseases requiring treatment of the female genitals and breast].
Horbach L; Hilgarth M; Melchert F; Stegner HE
Geburtshilfe Frauenheilkd; 1984 Oct; 44(10):627-35. PubMed ID: 6569843
[TBL] [Abstract][Full Text] [Related]
3. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours.
Venkitaraman R; Johnson B; Huddart RA; Parker CC; Horwich A; Dearnaley DP
BJU Int; 2007 Jul; 100(1):30-2. PubMed ID: 17552950
[TBL] [Abstract][Full Text] [Related]
4. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer].
Tang BJ; Li L; Xu J
Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406
[TBL] [Abstract][Full Text] [Related]
5. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
6. Laparoscopy in the diagnosis and management of ovarian cancer.
Qu JY; Sun AD; Lien LC
J Reprod Med; 1984 Jul; 29(7):483-8. PubMed ID: 6237194
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal fluid lactate dehydrogenase in ovarian cancer.
Schneider D; Halperin R; Langer R; Bukovsky I; Herman A
Gynecol Oncol; 1997 Sep; 66(3):399-404. PubMed ID: 9299252
[TBL] [Abstract][Full Text] [Related]
9. Recurrent ovarian carcinoma: diagnosis and second-line therapy.
Geary M; Foley M; Lenehan P; Murphy J; Fennelly J
Ir Med J; 1995; 88(2):68-70. PubMed ID: 7775151
[TBL] [Abstract][Full Text] [Related]
10. [CA-125 antigen].
Zakrzewska I
Postepy Hig Med Dosw; 2002; 56(1):29-38. PubMed ID: 11987487
[TBL] [Abstract][Full Text] [Related]
11. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
Petignat P; Vajda D; Obrist R
Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
Lukácskó I; Hernádi Z; Sápy T; Borsos A
Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
[TBL] [Abstract][Full Text] [Related]
13. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
Zervoudis S; Peitsidis P; Iatrakis G; Panourgias E; Koureas A; Navrozoglou I; Dubois JB
J BUON; 2007; 12(4):487-92. PubMed ID: 18067207
[TBL] [Abstract][Full Text] [Related]
15. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
16. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
[TBL] [Abstract][Full Text] [Related]
17. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Cane P; Azen C; Lopez E; Platt LD; Karlan BY
Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
[TBL] [Abstract][Full Text] [Related]
18. [Possibilities and limits of the study of tumor markers in the after-care of patients with ovarian cancer].
Kreienberg R
Gynakologe; 1986 Sep; 19(3):178-85. PubMed ID: 3770529
[No Abstract] [Full Text] [Related]
19. [Evaluation on non invasive diagnostic tests for the second look in epithelial ovarian cancer].
García Enguídanos A; Crespo Azanza E; Díaz Recaséns J; Lobo Samper F; Jorge Herrero JA; Sáinz de la Cuesta Abbad R
Rev Clin Esp; 1998 Aug; 198(8):502-5. PubMed ID: 9774878
[TBL] [Abstract][Full Text] [Related]
20. Second-look laparoscopy in ovarian cancer.
Xygakis AM; Politis GS; Michalas SP; Kaskarelis DB
J Reprod Med; 1984 Aug; 29(8):583-85. PubMed ID: 6237197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
